Sigilon Therapeutics to Present at the 2017 Biotech and Money Inv€$tival Showcase Conference in London

CAMBRIDGE, Mass., Nov. 10, 2017 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017. Details are as follows:

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromer™ technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics' co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

SOURCE Sigilon Therapeutics

Related Links

http://www.sigilon.com